Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG009301
- Development stage
- Phase 1
- Lead developer
- Cullgen
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
CG009301 is a highly selective, investigational small molecule degrader of GSPT1 (G1 to S phase transition 1), developed using Cullgen’s proprietary uSMITE platform for targeted protein degradation. It is designed as a proteolysis-targeting chimera (PROTAC) that induces the ubiquitination and subsequent proteasomal degradation of GSPT1, a protein implicated in cell cycle regulation and survival of malignant cells. The drug is being developed primarily for the treatment of relapsed or refractory hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and high-risk myelodysplastic syndromes (MDS). There is also potential for its use in solid tumors with MYC amplification. As of late 2024, the Chinese National Medical Products Administration has allowed an IND application for Phase I clinical trials in China[1][2][3][8].
- Brand names
- CG009301CG-009301CG 009301
- Other names
- CG009301CG-009301CG 009301
02
Targets
GSPT1 (G1 to S phase transition 1)CRBN (Cereblon)
Beyond the preview
Go deeper on CG009301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG009301.